Developer docs
API playgroundTry for free, no card

Search company profiles

Lieber Institute for Brain Development

Full company profile

uuid000ejji

Namestring
Lieber Institute for Brain Development
Legal namestring
Lieber Institute for Brain Development
Websiteurl
libd.org
Company typeenum
Private
Founded yearint
2011
Descriptiontext

The Lieber Institute for Brain Development (LIBD) is an independent nonprofit 501(c)(3) medical research institute founded in 2011 by philanthropists Steve and Connie Lieber and headquartered on the Johns Hopkins Medical Campus in Baltimore, Maryland. It employs 100+ scientists and operates 48,000 square feet of laboratory space dedicated to translating the genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances. Its research spans schizophrenia, depression, bipolar disorder, PTSD, autism, addiction, suicide, and aging-related conditions, with formal translational partnerships including Sheppard Pratt Hospital (70,000 patients/year) and Peking University (900+ subjects in a gene-environment study).

LIBD's core assets are the world's largest postmortem human brain repository dedicated to psychiatric research (nearly 5,000 brains with detailed clinical, demographic, and quality-control metadata), a 1,000+ human cell line repository, and a neuroimaging genetics database covering 3,000+ individuals. Underlying capabilities include single-nucleus RNA sequencing (producing the first-ever human habenula cell atlas), ADARB1 RNA editing analysis, and machine-learning-driven functional MRI analysis (Random Forest Multiple Regression). The institute integrates these capabilities into a genes-to-drugs pipeline combining medicinal chemistry, assay development, and in vivo pharmacology, with 4 candidate therapeutics currently in testing.

The organization's revenue model combines philanthropic donations (one-time gifts, monthly Brain Trust program, stock gifts, donor-advised funds, legacy giving) with research grants and government funding (NIH, National Science Foundation). The go-to-market is community-led: donor cultivation via newsletters (Lieber Notes), podcasts (The Rose Window), events, and storytelling around brain donor families (300+ per year). Outputs are distributed through 200+ peer-reviewed publications in high-impact journals and collaborative research programs with global academic and clinical institutions.

Short descriptiontext

The Lieber Institute for Brain Development (LIBD) is an independent nonprofit research institute on the Johns Hopkins Medical Campus that studies the genetic and molecular mechanisms of schizophrenia and related brain disorders. It operates the world's largest postmortem brain repository (~5,000 brains) and an active drug discovery pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuropsychiatric research, postmortem brain research, drug discovery pipeline, genomic neuroscience, imaging genetics
Industry3 codes
1Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryYes
2Neurogenetics & Rare Neurologic Diseases
CodeHLAKAIAOPrimaryNo
3Neurology & Psychiatry (CNS) Pharmaceuticals
CodeHLAIAAAFPrimaryNo
NAICS code1 code
  • Medical Laboratories621511
Product category
Neuroscience Research
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Donations and Philanthropy
TypeGrants Donations
Description

Primary revenue stream through individual donations (one-time, monthly Brain Trust program, stock gifts), donor-advised funds, legacy/planned giving, and tribute gifts. Tax-exempt nonprofit organization.

libd.org
2Research Grants and Government Funding
TypeProfessional Services
Description

Collaborative research funding from government sources including NIH and National Science Foundation, including notable US-China research collaborations.

libd.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Brain Trust
Description

Monthly giving program where supporters become part of a community of committed donors helping scientists uncover the root causes of mental illness

libd.org
Core offering1 text field

The Lieber Institute for Brain Development operates the world's largest postmortem brain repository dedicated to psychiatric research (nearly 5,000 human brains with paired clinical data, cell lines, and molecular samples) and a genes-to-drugs discovery pipeline that integrates medicinal chemistry, assay development, and in vivo pharmacology. The institute translates genetic and molecular insights on schizophrenia and related developmental brain disorders into novel therapeutic targets, biomarkers, and potential treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Nearly 5,000 human brains donated for research enabling unprecedented psychiatric disorder studies
+4 more records
Product overview1 text field

The Lieber Institute for Brain Development (LIBD) is an independent, nonprofit 501(c)(3) brain research and drug discovery institute offering a portfolio of research resources and programs rather than commercial products. The core offerings include the Brain Repository (nearly 5,000 postmortem brains, the largest collection worldwide for psychiatric research) and a Drug Discovery Pipeline integrating medicinal chemistry, assay development, and in vivo pharmacology. Supporting programs include the African Ancestry Neuroscience Research Initiative, a Human Cell Lines Repository (1,000+ lines), and the Brain Donor Program. Public-facing engagement products include The Rose Window podcast series and the Lieber Notes monthly newsletter. The institute also operates the Brain Trust monthly giving program for donor engagement.

Product and service6 records
1Human Brain Repository
CategoryResearch Biobank
Description

The world's largest collection of postmortem human brains dedicated to psychiatric research, with nearly 5,000 specimens, detailed clinical and demographic classifications, tissue, blood, patient-derived cell lines, RNA and DNA samples, and quality control data including postmortem interval, RNA integrity number, pH, and toxicology. Used by academic and clinical researchers studying neuropsychiatric disorders.

2Human Cell Lines Repository
CategoryResearch Resource
Description

A collection of 1,000+ human cell lines generated from clinical samples and postmortem brains, including lines from ~500 extensively studied individuals and over 500 individuals whose brains are also in the LIBD repository, made available to researchers for neuropsychiatric studies.

3Drug Discovery Pipeline
CategoryDrug Discovery
Description

A genes-to-drugs program integrating medicinal chemistry, assay development, and in vivo pharmacology with pharmacokinetics to identify and develop novel therapeutic molecules for psychiatric diseases, with four potential treatment options currently being tested.

4Brain Donor Program
CategoryResearch Program
Description

A program enabling families to donate their loved one's brain tissue for mental health research, feeding the LIBD brain repository with approximately 300+ family donations per year to support psychiatric research.

5African Ancestry Neuroscience Research Initiative (AANRI)
CategoryResearch Program
Description

A multi-institutional program addressing health disparities in neuroscience by increasing representation of African ancestry populations in brain research (<5% of current participants are Black), with pillars including community engagement, researcher development, and equitable research practices.

6The Rose Window Podcast
CategoryContent Program
Description

A six-episode podcast series hosted by Dr. Daniel Weinberger with Ryan Cummins discussing the science of mental health and brain research, distributed on Apple Podcasts and Spotify as a donor and community engagement offering.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sheppard Pratt-Lieber Research Institute partnership: Sheppard Pratt is the largest neuropsychiatric clinical care program in the Mid-Atlantic States, treating 70,000 patients/year. Collaborative clinical research includes studies on Traumatic Brain Injury (TBI), Mild Cognitive Impairment (MCI), and Adult Autism. This translational clinical extension brings research from bench to bedside.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Peking University-Lieber Translational Neuropsychiatry Research Institute: A multi-year formal collaboration with China's leading research university. Includes the largest combined NIH, National Science Foundation of China award for US-Chinese medical research to-date. Gene x environment study of brain development has evaluated over 900 subjects.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Affiliated with Johns Hopkins University School of Medicine. Located on the Johns Hopkins Medical Campus with 48,000 sq ft of state-of-the-art laboratory space. LIBD is the largest non-Johns Hopkins University employer in the East Baltimore inner-city development project.

4African Ancestry Neuroscience Research Initiative (AANRI) Partners
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Multi-institutional initiative addressing health disparities in neuroscience research. Partners include academic institutions and community organizations working to increase representation of African ancestry populations in brain research (less than 5% of brain research participants are Black). Focuses on pillars of community engagement, researcher development, and equitable research practices.

libd.org
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration on Down syndrome study led by scientists at Icahn School of Medicine at Mount Sinai and Johns Hopkins University examining fetal brain tissue from individuals with Down syndrome.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lieber Institute for Brain Development

Neuroscience Researchlibd.org

The Lieber Institute for Brain Development (LIBD) is an independent nonprofit research institute on the Johns Hopkins Medical Campus that studies the genetic and molecular mechanisms of schizophrenia and related brain disorders. It operates the world's largest postmortem brain repository (~5,000 brains) and an active drug discovery pipeline.

What Lieber Institute for Brain Development does

The Lieber Institute for Brain Development (LIBD) is an independent nonprofit 501(c)(3) medical research institute founded in 2011 by philanthropists Steve and Connie Lieber and headquartered on the Johns Hopkins Medical Campus in Baltimore, Maryland. It employs 100+ scientists and operates 48,000 square feet of laboratory space dedicated to translating the genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances. Its research spans schizophrenia, depression, bipolar disorder, PTSD, autism, addiction, suicide, and aging-related conditions, with formal translational partnerships including Sheppard Pratt Hospital (70,000 patients/year) and Peking University (900+ subjects in a gene-environment study).

LIBD's core assets are the world's largest postmortem human brain repository dedicated to psychiatric research (nearly 5,000 brains with detailed clinical, demographic, and quality-control metadata), a 1,000+ human cell line repository, and a neuroimaging genetics database covering 3,000+ individuals. Underlying capabilities include single-nucleus RNA sequencing (producing the first-ever human habenula cell atlas), ADARB1 RNA editing analysis, and machine-learning-driven functional MRI analysis (Random Forest Multiple Regression). The institute integrates these capabilities into a genes-to-drugs pipeline combining medicinal chemistry, assay development, and in vivo pharmacology, with 4 candidate therapeutics currently in testing.

The organization's revenue model combines philanthropic donations (one-time gifts, monthly Brain Trust program, stock gifts, donor-advised funds, legacy giving) with research grants and government funding (NIH, National Science Foundation). The go-to-market is community-led: donor cultivation via newsletters (Lieber Notes), podcasts (The Rose Window), events, and storytelling around brain donor families (300+ per year). Outputs are distributed through 200+ peer-reviewed publications in high-impact journals and collaborative research programs with global academic and clinical institutions.

Lieber Institute for Brain Development firmographics

Firmographics
Name
Lieber Institute for Brain Development
Legal name
Lieber Institute for Brain Development
Website
https://libd.org
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
The Lieber Institute for Brain Development (LIBD) is an independent nonprofit research institute on the Johns Hopkins Medical Campus that studies the genetic and molecular mechanisms of schizophrenia and related brain disorders. It operates the world's largest postmortem brain repository (~5,000 brains) and an active drug discovery pipeline.
Ownership category
akta.pro rank

Lieber Institute for Brain Development industry classification

Industry
Product category
Neuroscience Research
NAICS
Medical Laboratories (621511)
akta.pro primary industry
Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
akta.pro secondary industries
Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

  • Neuropsychiatric research
  • Postmortem brain research
  • Drug discovery pipeline
  • Genomic neuroscience
  • Imaging genetics

Where Lieber Institute for Brain Development is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Lieber Institute for Brain Development business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Donations and Philanthropy: Primary revenue stream through individual donations (one-time, monthly Brain Trust program, stock gifts), donor-advised funds, legacy/planned giving, and tribute gifts. Tax-exempt nonprofit organization.
  2. Research Grants and Government Funding: Collaborative research funding from government sources including NIH and National Science Foundation, including notable US-China research collaborations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Lieber Institute for Brain Development product offering

Product offering

Core offering

The Lieber Institute for Brain Development operates the world's largest postmortem brain repository dedicated to psychiatric research (nearly 5,000 human brains with paired clinical data, cell lines, and molecular samples) and a genes-to-drugs discovery pipeline that integrates medicinal chemistry, assay development, and in vivo pharmacology. The institute translates genetic and molecular insights on schizophrenia and related developmental brain disorders into novel therapeutic targets, biomarkers, and potential treatments.

Product overview

The Lieber Institute for Brain Development (LIBD) is an independent, nonprofit 501(c)(3) brain research and drug discovery institute offering a portfolio of research resources and programs rather than commercial products. The core offerings include the Brain Repository (nearly 5,000 postmortem brains, the largest collection worldwide for psychiatric research) and a Drug Discovery Pipeline integrating medicinal chemistry, assay development, and in vivo pharmacology. Supporting programs include the African Ancestry Neuroscience Research Initiative, a Human Cell Lines Repository (1,000+ lines), and the Brain Donor Program. Public-facing engagement products include The Rose Window podcast series and the Lieber Notes monthly newsletter. The institute also operates the Brain Trust monthly giving program for donor engagement.

Differentiator

Problem solved

Functional benefit

Brands

  • Brain Trust: Monthly giving program where supporters become part of a community of committed donors helping scientists uncover the root causes of mental illness

Products and services

  • Human Brain Repository The world's largest collection of postmortem human brains dedicated to psychiatric research, with nearly 5,000 specimens, detailed clinical and demographic classifications, tissue, blood, patient-derived cell lines, RNA and DNA samples, and quality control data including postmortem interval, RNA integrity number, pH, and toxicology. Used by academic and clinical researchers studying neuropsychiatric disorders.
  • Human Cell Lines Repository A collection of 1,000+ human cell lines generated from clinical samples and postmortem brains, including lines from ~500 extensively studied individuals and over 500 individuals whose brains are also in the LIBD repository, made available to researchers for neuropsychiatric studies.
  • Drug Discovery Pipeline A genes-to-drugs program integrating medicinal chemistry, assay development, and in vivo pharmacology with pharmacokinetics to identify and develop novel therapeutic molecules for psychiatric diseases, with four potential treatment options currently being tested.
  • Brain Donor Program A program enabling families to donate their loved one's brain tissue for mental health research, feeding the LIBD brain repository with approximately 300+ family donations per year to support psychiatric research.
  • African Ancestry Neuroscience Research Initiative (AANRI) A multi-institutional program addressing health disparities in neuroscience by increasing representation of African ancestry populations in brain research (<5% of current participants are Black), with pillars including community engagement, researcher development, and equitable research practices.
  • The Rose Window Podcast A six-episode podcast series hosted by Dr. Daniel Weinberger with Ryan Cummins discussing the science of mental health and brain research, distributed on Apple Podcasts and Spotify as a donor and community engagement offering.

Quantifiable outcome

  • Nearly 5,000 human brains donated for research enabling unprecedented psychiatric disorder studies
  • +4 more outcomes

Companies that use Lieber Institute for Brain Development

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Lieber Institute for Brain Development technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Lieber Institute for Brain Development partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, strategic and minor.

  • Sheppard Pratt HospitalcoreStrategic or Co-development PartnerSheppard Pratt-Lieber Research Institute partnership: Sheppard Pratt is the largest neuropsychiatric clinical care program in the Mid-Atlantic States, treating 70,000 patients/year. Collaborative clinical research includes studies on Traumatic Brain Injury (TBI), Mild Cognitive Impairment (MCI), and Adult Autism. This translational clinical extension brings research from bench to bedside.
  • Peking UniversitycoreStrategic or Co-development PartnerPeking University-Lieber Translational Neuropsychiatry Research Institute: A multi-year formal collaboration with China's leading research university. Includes the largest combined NIH, National Science Foundation of China award for US-Chinese medical research to-date. Gene x environment study of brain development has evaluated over 900 subjects.
  • Johns Hopkins University School of MedicinecoreStrategic or Co-development PartnerAffiliated with Johns Hopkins University School of Medicine. Located on the Johns Hopkins Medical Campus with 48,000 sq ft of state-of-the-art laboratory space. LIBD is the largest non-Johns Hopkins University employer in the East Baltimore inner-city development project.
  • African Ancestry Neuroscience Research Initiative (AANRI) PartnersstrategicStrategic or Co-development PartnerMulti-institutional initiative addressing health disparities in neuroscience research. Partners include academic institutions and community organizations working to increase representation of African ancestry populations in brain research (less than 5% of brain research participants are Black). Focuses on pillars of community engagement, researcher development, and equitable research practices.
  • Icahn School of Medicine at Mount SinaiminorStrategic or Co-development PartnerResearch collaboration on Down syndrome study led by scientists at Icahn School of Medicine at Mount Sinai and Johns Hopkins University examining fetal brain tissue from individuals with Down syndrome.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Lieber Institute for Brain Development competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Lieber Institute for Brain Development social profiles

Digital presence

Lieber Institute for Brain Development compliance and trust

Trust signal

Compliance1 record

Lieber Institute for Brain Development financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lieber Institute for Brain Development leadership team

Management profile

Number of profiles

Profiles2 records

Lieber Institute for Brain Development funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lieber Institute for Brain Development M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lieber Institute for Brain Development

What does Lieber Institute for Brain Development do?

The Lieber Institute for Brain Development operates the world's largest postmortem brain repository dedicated to psychiatric research (nearly 5,000 human brains with paired clinical data, cell lines, and molecular samples) and a genes-to-drugs discovery pipeline that integrates medicinal chemistry, assay development, and in vivo pharmacology. The institute translates genetic and molecular insights on schizophrenia and related developmental brain disorders into novel therapeutic targets, biomarkers, and potential treatments.

Is Lieber Institute for Brain Development a public or private company?

Lieber Institute for Brain Development is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Lieber Institute for Brain Development founded?

Lieber Institute for Brain Development was founded in 2011. It employs 101 to 250 people.

Where is Lieber Institute for Brain Development based?

Lieber Institute for Brain Development is headquartered in Baltimore, United States, in the North America region.

How does Lieber Institute for Brain Development make money?

Two revenue lines are on record. Donations and Philanthropy is the primary driver. The others are research Grants and Government Funding.

Does Lieber Institute for Brain Development have an API?

No public API is recorded for Lieber Institute for Brain Development.

What industry is Lieber Institute for Brain Development in?

Lieber Institute for Brain Development's product category is Neuroscience Research. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAKAIAO, Neurogenetics & Rare Neurologic Diseases. Its NAICS code is 621511.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsLong‑Range Gene Networks Uncover 641 New Schizophrenia‑Associated GenesA study in Nature Genetics identified 641 previously unrecognized schizophrenia-associated genes using co-expression-based models that capture long-range regulatory effects. The models, applied to data from over 102,000 individuals, improved gene-expression prediction and highlighted pathways in glutamate signaling and neurodevelopment.GlobeNewswireBullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric DisordersBullFrog AI and the Lieber Institute for Brain Development identified novel drug targets for neuropsychiatric disorders, including major depression, schizophrenia, and bipolar disorder. Using AI and graph analytics, they clustered patients by gene isoform expression, revealing biological subtypes and key genes. The company is now applying Causal AI to prioritize targets for wet-lab validation.GlobeNewswireBullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChipBullFrog AI CEO Vin Singh and Lieber Institute CEO Daniel R. Weinberger will host a fireside chat on March 5, 2024, to discuss their collaboration's findings. The partnership stratified brain expression data from over 2,800 samples, identifying biological subtypes across psychiatric disorders. The results may enable targeted treatments and revenue-generating partnerships.GlobeNewswireBullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression DataBullFrog AI and the Lieber Institute for Brain Development announced early results from their collaboration, which stratified brain expression data from over 2,800 brain samples. The findings cluster subjects by biological data, revealing distinct pathways and subtypes within disorders like schizophrenia and bipolar disorder. The partnership aims to enable personalized treatments and potential revenue-generating partnerships.PR NewswireBlackbird Labs, a Next-Generation Life Sciences Accelerator, Launches with $100 Million and Foundational Collaboration with Johns Hopkins UniversityBlackbird Labs, a life sciences accelerator, launched with a $100 million founding grant from The Stephen and Renee Bisciotti Foundation and research collaborations with Johns Hopkins, the University of Maryland, Baltimore, and the Lieber Institute for Brain Development. The accelerator focuses on novel therapeutics across modalities including inflammation, neurological, genetic, and cancer diseases.GlobeNewswireBullFrog AI Announces Three-Year Global StrategicBullFrog AI announced a three-year partnership with the Lieber Institute for Brain Development to mine postmortem brain data using its bfLEAP platform. The collaboration aims to identify gene-pathway relationships in neuropsychiatric disorders, with a one-year data exclusivity and two-year extension option. BullFrog AI will receive access to LIBD's brain data and share revenue from commercialized products.PR NewswireThe Lieber Institute for Brain Development Announces Nomination Period for the 2019 Constance Lieber Prize for Innovation in Developmental NeuroscienceThe Lieber Institute for Brain Development has announced the opening of the nomination period for the 2019 Constance Lieber Prize for Innovation in Developmental Neuroscience. The biennial award, which includes a $100,000 cash prize, is open to investigators under 55 who have made transformative contributions to the field with clinical implications. Nominations are accepted until January 31, 2019, with the award to be presented at Johns Hopkins School of Medicine.PR NewswireHistoric Partnership Aims to Accelerate the Discovery of Novel Treatment Targets for Posttraumatic Stress Disorder (PTSD)The Lieber Institute for Brain Development (LIBD) and the U.S. Department of Veterans Affairs (VA) announced a research partnership to identify novel therapeutic targets for posttraumatic stress disorder (PTSD). The collaboration will utilize LIBD's postmortem brain repository to analyze gene expression in brain regions affected by PTSD, aiming to develop new treatments for this condition.PR NewswireThe Lieber Institute for Brain Development to Honor Founder's Legacy Through Establishment of the Constance Lieber Prize for Innovation in Developmental NeuroscienceThe Lieber Institute for Brain Development announced the establishment of the Constance Lieber Prize for Innovation in Developmental Neuroscience, a $100,000 award to be given every two years to an investigator under 55 who has made transformative contributions in developmental neuroscience with clinical implications. The prize honors Connie Lieber, one of the Institute's founders and a transformative figure in private funding for brain research who led the Brain and Behavior Research Foundation for over 25 years before co-founding the Lieber Institute with her husband Steve Lieber. The inaugural award will be presented at a symposium in June 2017.